The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease

Parkinson's disease (PD) as the most important movement disorder is characterized by a progressive loss of nigral dopamine neurons and a subsequent degeneration within several other transmitter systems. Functional brain imaging with positron emission tomography (PET) and the radiotracer 18‐fluorodopa (FDOPA) is capable to quantify the deficiency of dopamine synthesis and storage within pre‐synaptic striatal nerve terminals. Therefore, FDOPA‐PET allows the diagnosis of PD in early disease stages and the differentiation of clinically unclear cases from other movement disorders, e.g. essential tremor. Additionally, FDOPA‐PET imaging permits the follow‐up of disease progression, the assessment of medical and surgical PD therapy strategies with possible neuroprotective properties and the detection of pre‐clinical disease in subjects at risk for the disorder. The classical domain of morphological magnetic resonance imaging (MRI) is the differentiation of symptomatic Parkinsonism from PD. However, recent advances in MRI data acquisition and analysis techniques demonstrated MRI to be also a valuable tool for detection of nigral pathology in PD and for differentiation of neurodegenerative disorders with atypical Parkinsonism.

[1]  W. Heiss,et al.  [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease , 2003, Clinical Neurology and Neurosurgery.

[2]  W. Heiss,et al.  Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  Dorothee P Auer,et al.  T2*-weighted MRI differentiates multiple system atrophy from Parkinson’s disease , 2002, Neurology.

[4]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[5]  C Kremser,et al.  Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.

[6]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[7]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[8]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[9]  David J. Brooks,et al.  A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.

[10]  W D Heiss,et al.  Increased pineal Fdopa uptake is related to severity of Parkinson's disease – A PET study , 2001, Journal of pineal research.

[11]  W D Heiss,et al.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the Parkin gene , 2001, Annals of neurology.

[12]  F. Tison,et al.  Oral zolmitriptan is effective in the acute treatment of cluster headache , 2000, Neurology.

[13]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Alavi,et al.  Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[16]  Ornella Rimoldi,et al.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.

[17]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[18]  Karl J. Friston,et al.  Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[19]  K. Marder,et al.  Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.

[20]  R. Hardie,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F] dopa PET , 1999, Journal of neurology, neurosurgery, and psychiatry.

[21]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[22]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[23]  S. Kish,et al.  Dystonia with motor delay in compound heterozygotes for GTP‐cyclohydrolase I gene mutations , 1998, Annals of neurology.

[24]  C. Mathias,et al.  Clinical usefulness of magnetic resonance imaging in multiple system atrophy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[25]  I. Saatci,et al.  Cranial MR findings in Wilson's disease , 1997, Acta radiologica.

[26]  K Wienhard,et al.  Functional effects of striatal dysfunction in Parkinson disease. , 1997, Archives of neurology.

[27]  D J Burn,et al.  Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.

[28]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[29]  M. Sasaki,et al.  Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms , 1996, Journal of the Neurological Sciences.

[30]  D J Brooks,et al.  Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[31]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[32]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[33]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[34]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[35]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  K. Herholz,et al.  Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits , 1994, Annals of neurology.

[37]  D J Brooks,et al.  Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[38]  D B Calne,et al.  Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.

[39]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[40]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[41]  Alan C. Evans,et al.  Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[43]  H. Karbe,et al.  Positron emission tomography demonstrates frontal cortex and basal ganglia hypometabolism in dystonia , 1992, Neurology.

[44]  P. Thompson,et al.  Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.

[45]  J R Moeller,et al.  The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[46]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[47]  D. Loring,et al.  Hallervorden‐spatz syndrome: Clinical and magnetic resonance imaging correlations , 1988, Annals of neurology.

[48]  A J Lees,et al.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.

[49]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[50]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[51]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[53]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[54]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[56]  Alexander Storch,et al.  Early diagnosis of Parkinson’s disease , 2006, Journal of Neurology.

[57]  G. Sawle,et al.  An [ 18 F]dopa-PET and clinical study of the rate of progression in Parkinson's disease , 2005 .

[58]  J. Booij,et al.  beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson ' s disease , 2003 .

[59]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[60]  J V Hajnal,et al.  A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. , 2001, Neurology.

[61]  D. Brooks.  Functional imaging studies in corticobasal degeneration. , 2000, Advances in neurology.

[62]  D. Brooks,et al.  Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. , 2000, Journal of neural transmission. Supplementum.

[63]  G. Sawle,et al.  The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. , 1996, Advances in neurology.

[64]  Y. Tateno,et al.  Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. , 1993, Advances in neurology.

[65]  K. Miyasaka,et al.  [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image]. , 1992, Rinshō shinkeigaku Clinical neurology.

[66]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.